HBI Deals+Insights / M&A/IPOs
British drugmaker GSK has acquired Nuvalent, a Boston-based clinical-stage biopharmaceutical company focused on precisely targeted oncology therapies, for an equity value of $10.6 billion (~£8 billion).





